Jorg Frei

This inventor holds 23 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Ciba-Geigy Corporation, Novartis Ag. Active years: 1976-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jorg Frei. Retrieved from https://idiyas.com/inventor/jorg-frei

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 8

Forward Citations = 249(Granted Patents)

Location History:

Schonenbuch, CH (1976 - 1983)
Holstein, CH (1982 - 2000)

Company Filing History:

18 out of 6,858

Ciba-Geigy Corporation

Years Active: 1976-2000

Loading Chart...

Areas of Expertise:

Pyrrolopyrimidines

Pyrazole Derivatives

Aminooxy Compounds

Imidazole Derivatives

Bipyridine Compounds

Hydrazones

Ornithine Decarboxylase Inhibitors

Biaryl Compounds

Pharmaceutical Compositions

SAMDC Inhibitors

Cyclic Aminooxy Compounds

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6140332 - Pyrrolopyrimidines and processes for the preparation thereof (2000-10-31),

2. 6140317 - Pyrrolopyrimidines and processes for their preparation (2000-10-31),

3. 5981533 - Pyrazole derivatives and processes for the preparation thereof (1999-11-09),

4. 5840911 - Imidazole derivatives, their preparation and their use as (1998-11-24),

5. 5834486 - Piperidinyl-2-alkyl, substituted linear polyamines for the reduction of (1998-11-10),

6. 5639911 - Hydrazones (1997-06-17),

7. 5627215 - Unsaturate amino compounds for use as anticancer and antiprotozoic agent (1997-05-06),

8. 5516806 - Ornithine decarboxylase inhibiting cyclic aminooxy compounds (1996-05-14),

9. 5395855 - Hydrazones (1995-03-07),

10. 5376685 - Arylhydrazones using as SAMDC inhibitors (1994-12-27),

11. 5354761 - Bipyridyls (1994-10-11),

12. 5322852 - Aminooxy piperidines as ornithine decarboxylase inhibitors (1994-06-21),

13. 5238941 - Arylhydrazones and pharmaceutical compositions thereof (1993-08-24),

14. 5169867 - Hydroxylamine compounds (1992-12-08),

15. 5118709 - Arylhydrazones and pharmaceutical compositions containing the same (1992-06-02),

Title: Innovations of Jorg Frei in the Pharmaceutical Industry

Introduction

Jorg Frei, a prolific inventor based in Holstein, Switzerland, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 23 patents, he stands out as a key figure in the innovation of chemical compounds that have potential applications in various medical therapies.

Latest Patents

Among his recent contributions, Frei has developed patents related to Pyrrolopyrimidines and processes for their preparation. These innovative compounds hold promise for advancing therapeutic options in the industry, showcasing his commitment to enhancing medicinal chemistry.

Career Highlights

Jorg Frei's impressive career includes tenures at renowned organizations such as Ciba-Geigy Corporation and Novartis AG. His work within these companies has not only contributed to their advancements but has also paved the way for future innovations in drug development and synthesis.

Collaborations

Throughout his career, Jorg has collaborated with noteworthy individuals in the field, including Jaroslav Stanek and Giorgio Caravatti. These collaborations have further enriched his research and development endeavors, demonstrating the importance of teamwork in fostering innovation.

Conclusion

Jorg Frei's dedication to his craft and his substantial contributions to pharmaceutical innovation exemplify the vital role inventors play in enhancing healthcare through new inventions. His extensive patent portfolio reflects a career marked by creativity and collaboration, making him a significant figure in the industry.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]